6-(2-methoxyethoxy)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine | 1000159-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(2-methoxyethoxy)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine
• 英文别名: 6-(2-Methoxyethoxy)-3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazine
• CAS: 1000159-07-8
• 化学式: C₁₆H₁₄F₃N₃O₃
• 分子量: 353.301
• InChiKey: HHRFSNJVCPRJOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  57.9
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals
  申请人：PRIEN Olaf

  公开号：US20090093475A1

  公开（公告）日：2009-04-09

  The invention relates to novel inhibitors of kinases of the general formula (I): in which Q and R 1 are defined in the claims, method for preparing such inhibitors, intermediates for preparing such inhibitors and uses of such inhibitors.

  这项发明涉及一般式(I)的新型激酶抑制剂： 其中Q和R1在权利要求中有定义，制备这种抑制剂的方法，制备这种抑制剂的中间体以及这种抑制剂的用途。
• [EN] HETEROCYCLIC PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE HÉTÉROCYCLIQUES
  申请人：TOLERO PHARMACEUTICALS INC

  公开号：WO2013013188A1

  公开（公告）日：2013-01-24

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一的蛋白激酶（I）、（II）或（III）：或其立体异构体、前药、互变异构体或药用可接受盐，其中R、R1、R2和X如本文所定义。还公开了在治疗癌症、自身免疫、炎症和其他Pim激酶相关疾病中使用这些蛋白激酶的组合物和方法。
• IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：Xu Yong

  公开号：US20120058997A1

  公开（公告）日：2012-03-08

  The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

  本发明提供了蛋白激酶抑制剂，包括以下结构（I）和（II）的咪唑[1,2-b]吡啶和吡唑[1,5-a]嘧啶化合物或其立体异构体、前药或药物可接受的盐，其中R、R1、R2和X如本文所定义。还公开了将其用于治疗癌症和其他Pim激酶相关疾病的组合物和方法。
• HETEROCYCLIC PROTEIN KINASE INHIBITORS
  申请人：Xu Yong

  公开号：US20140329807A1

  公开（公告）日：2014-11-06

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一（I），（II）或（III）的蛋白激酶：或其立体异构体，前药，互变异构体或药学上可接受的盐，其中R，R1，R2和X如本文所定义。还公开了在治疗癌症，自身免疫，炎症和其他Pim激酶相关疾病中使用相同的组合物和方法。
• OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS
  申请人：Bayer Intellectual Property GmbH

  公开号：US20140135323A1

  公开（公告）日：2014-05-15

  The invention relates to novel inhibitors of kinases of the general formula (I): in which Q and R 1 are defined in the claims, method for preparing such inhibitors, intermediates for preparing such inhibitors and uses of such inhibitors.

  该发明涉及一种通式（I）所示的激酶的新型抑制剂，其中Q和R1在权利要求中定义，制备这种抑制剂的方法，制备这种抑制剂的中间体以及使用这种抑制剂。